MicroRNA 2114 (MIR2114)

MicroRNA 2114 (MIR2114) is a short, non-coding RNA molecule (miRNA) predicted to function in post-transcriptional regulation of gene expression, mainly by imperfect base pairing with target mRNAs, resulting in translational inhibition or mRNA destabilization. Like other microRNAs, MIR2114 is transcribed as part of longer precursors processed by DROSHA and DICER enzymes, then loaded onto the RNA-induced silencing complex (RISC) to bind target mRNAs[3]. While most human miRNAs broadly impact cellular processes such as cell cycle, apoptosis, and differentiation, there is minimal literature on the specific function or validated targets of MIR2114 in humans[3][7]. No interacting drugs, mechanisms of action, known use as a biomarker, or specific safety concerns are documented for MIR2114. Current gene resources (GeneCards, HGNC) list MIR2114 as a miRNA gene, but there is no evidence it is a validated therapeutic target or has a defined and essential biological role. Accordingly, it is likely this is not a commonly recognized or biologically prioritized target in research or clinical practice[3]. - There is no direct evidence of MIR2114 being therapeutically targeted or validated in disease biology. - It is possible that the entry is misapplied or the target is not actually relevant as a standalone entity for drug development. If you require structured information, this data indicates that "microRNA 2114" is not established as a therapeutic target, and there is little or no information regarding its functional or pharmacological importance[3].

Other names

hsa-mir-2114MIR2114hsa-miR-2114